Company Profile

Kadmon Corporation LLC
Profile last edited on: 12/3/2023      CAGE: 6ALL0      UEI: EZRWFE9KAEF6

Business Identifier: Therapeutic drugs for the treatment of oncology, immunology and infectious or neurodegenerative diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

450 East 29th Street 5th Floor
New York, NY 10016
   (212) 308-6000
Location: Single
Congr. District: 12
County: New York

Public Profile

Kadmon Holdings, Inc.,(NYSE:KDMN) is a biopharmaceutical company working in small molecules and biologics space for application in autoimmune and fibrotic, oncology, and genetic diseases. The company offers a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including those indicated for the management of rare diseases. The firm's lead product candidates include KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases; Tesevatinib, an oral tyrosine kinase inhibitor that is in Phase II clinical studies for use in the treatment of non-small cell lung cancer and glioblastoma, as well as for treating autosomal dominant polycystic kidney disease; and KD034 that is used for the treatment of Wilson's disease, a genetic liver disease. Kadmon Holdings, Inc. has a strategic collaborations and license agreements with a wide range of entities foreign and domestic

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $172,052
Project Title: Discovery of Inhibitors of the Metabolic Oncogene 3-Phosphoglycerate Dehydrogenas
2012 1 NIH $184,624
Project Title: Treatment Of Cytomegalovirus By Inhibition Of Host Lipid Synthesis

Key People / Management

  Samuel D Waksal -- Founder, Chairman and CEO

  Bryson D Bennett

  Lawrence Cohen -- Senior Vice President, Business Development

  Michael J Howerton -- Chief Operating Officer, Chief Financial Officer & Executive Vice President

  Peter Mills

  Kellen Leonard Olszewski

  John Ryan -- Chief Medical Officer & Executive Vice President

  Adriann Sax -- Executive Vice President, Chief Commercial Officer